Literature DB >> 17260087

SV40 association with human malignancies and mechanisms of tumor immunity by large tumor antigen.

D B Lowe1, M H Shearer, C A Jumper, R C Kennedy.   

Abstract

SV40 was discovered as a contaminate of poliovirus vaccine lots distributed to millions of individuals in the United States between 1955 and 1963 while contaminated vaccine batches were later circulated worldwide. After SV40 was observed to cause in vitro animal and human cell transformations and in vivo tumor formations in animals, the search for a connection between the virus and human malignancies has continued to the present day. Different molecular methods have been used to detect SV40 gene products in a variety of human cancers, though SV40 causality in these tumor types has yet to be established. These data, however, are not without controversial issues related to inconclusive SV40 serological and epidemiological evidence alongside tools and methodologies that may contribute to false-positive results in human specimens. This review will also explore how vaccination against SV40 protein products may be used to help prevent and treat individuals with SV40-expressing cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260087     DOI: 10.1007/s00018-007-6414-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  8 in total

1.  Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

2.  CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.

Authors:  Joel F Aldrich; Devin B Lowe; Michael H Shearer; Richard E Winn; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

3.  Evidence of simian virus 40 exposure in a colony of captive baboons.

Authors:  Landon W Westfall; Michael H Shearer; Cynthia A Jumper; Gary L White; James F Papin; Richard Eberle; Janet S Butel; Robert K Bright; Ronald C Kennedy
Journal:  Virology       Date:  2008-05-16       Impact factor: 3.616

4.  SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis.

Authors:  Thomas Henzi; Walter-Vincent Blum; Martine Pfefferli; Tadeusz J Kawecki; Valerie Salicio; Beat Schwaller
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

5.  Human polyomaviruses in skin diseases.

Authors:  Ugo Moens; Maria Ludvigsen; Marijke Van Ghelue
Journal:  Patholog Res Int       Date:  2011-09-12

Review 6.  Antiviral Activities of Human Host Defense Peptides.

Authors:  David C Brice; Gill Diamond
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

7.  Transgenic mouse models of breast cancer.

Authors:  Angelina T Regua; Austin Arrigo; Daniel Doheny; Grace L Wong; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2021-06-06       Impact factor: 9.756

8.  Fanconi anemia patients are more susceptible to infection with tumor virus SV40.

Authors:  Manola Comar; Daniela De Rocco; Enrico Cappelli; Nunzia Zanotta; Roberta Bottega; Johanna Svahn; Piero Farruggia; Aldo Misuraca; Fabio Corsolini; Carlo Dufour; Anna Savoia
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.